Callan Family Office LLC Increases Stock Position in United Therapeutics Corporation $UTHR

Key Points

• Callan Family Office LLC increased its stake in United Therapeutics Corporation by 258.3%, acquiring an additional 2,500 shares, bringing its total holdings to 3,468 shares valued at approximately $997,000.
• Several institutional investors made significant investments in UTHR, including Vaughan Nelson Investment Management acquiring shares worth approximately $101.35 million and Amundi increasing its ownership by 198.8%.
• The stock price of United Therapeutics has recently seen fluctuations, opening at $440.00 with a market cap of $19.85 billion, while analysts have a moderate buy rating with a target price averaging $457.21.

Callan Family Office LLC lifted its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 258.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,468 shares of the biotechnology company's stock after buying an additional 2,500 shares during the quarter. Callan Family Office LLC's holdings in United Therapeutics were worth $997,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of UTHR. Vaughan Nelson Investment Management L.P. purchased a new stake in shares of United Therapeutics during the 1st quarter valued at approximately $101,354,000. Nuveen LLC purchased a new stake in United Therapeutics in the 1st quarter worth approximately $83,533,000. Amundi lifted its stake in United Therapeutics by 198.8% in the 1st quarter. Amundi now owns 350,193 shares of the biotechnology company's stock worth $107,635,000 after purchasing an additional 232,988 shares in the last quarter. Acadian Asset Management LLC lifted its stake in United Therapeutics by 1,657.8% in the 1st quarter. Acadian Asset Management LLC now owns 179,205 shares of the biotechnology company's stock worth $55,217,000 after purchasing an additional 169,010 shares in the last quarter. Finally, Invesco Ltd. lifted its stake in United Therapeutics by 46.1% in the 1st quarter. Invesco Ltd. now owns 465,115 shares of the biotechnology company's stock worth $143,381,000 after purchasing an additional 146,664 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $440.00 on Monday. The company's fifty day moving average price is $372.27 and its 200-day moving average price is $323.78. The firm has a market capitalization of $19.85 billion, a price-to-earnings ratio of 17.17, a PEG ratio of 4.82 and a beta of 0.66. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $459.48.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). The company had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.United Therapeutics's quarterly revenue was up 11.7% on a year-over-year basis. During the same period in the previous year, the company earned $5.85 EPS. As a group, equities research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In related news, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $417.64, for a total transaction of $9,396,900.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $308.75, for a total transaction of $3,396,250.00. Following the transaction, the executive vice president directly owned 36,781 shares in the company, valued at approximately $11,356,133.75. This represents a 23.02% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 261,935 shares of company stock worth $105,561,472. 10.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

UTHR has been the topic of several recent analyst reports. Morgan Stanley increased their target price on shares of United Therapeutics from $328.00 to $435.00 and gave the stock an "equal weight" rating in a research note on Friday. Oppenheimer increased their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an "outperform" rating in a research note on Friday, September 5th. Royal Bank Of Canada initiated coverage on shares of United Therapeutics in a research note on Friday, September 26th. They issued an "outperform" rating and a $569.00 target price on the stock. Weiss Ratings reiterated a "hold (c+)" rating on shares of United Therapeutics in a research note on Wednesday, October 8th. Finally, JPMorgan Chase & Co. lowered their target price on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research note on Tuesday, July 8th. Ten equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. Based on data from MarketBeat, United Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $457.21.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.